HIV-1-INFECTION

This study looks at people with HIV whose current medication (dolutegravir) is no longer working well due to drug resistance. It compares two options: staying on dolutegravir or switching to a different drug (darunavir boosted by ritonavir). The goal is to see which approach bett…

This study tests whether a special HIV vaccine, combined with an immune-boosting drug and two powerful antibodies, can help people with HIV control the virus on their own after stopping daily antiretroviral therapy. The trial involves 36 adults who started HIV treatment soon afte…

This early-stage study tests a new antibody called BNT351 in up to 61 adults, both with and without HIV. The main goal is to check safety and how the body processes the antibody. In people with HIV, researchers will also measure if the antibody can lower the amount of virus in th…

This study compares two different HIV medication combinations in people who have never taken HIV drugs before. The goal is to see if a newer drug called doravirine works just as well as the standard drug dolutegravir. About 610 adults with HIV-1 will take either doravirine or dol…

This study tests whether two antibodies given by IV every 8 weeks can keep HIV under control, replacing daily oral medication. About 75 adults with well-controlled HIV will either receive the antibody combo or continue their usual daily pills for 48 weeks. The goal is to see if t…

This study offers continued access to HIV medications for up to 350 children and adolescents who finished earlier Gilead HIV treatment studies. Participants will either stay on their current drug or switch to a newer combination pill. The main goal is to ensure they keep receivin…

This study is testing a long-acting injectable HIV medication (cabotegravir and rilpivirine) in children aged 2 to 12 who already have their HIV under control with daily pills. The goal is to see if switching to monthly or every-other-month shots is safe, tolerable, and works as …

This study is testing a new combination of two HIV medicines (bictegravir and lenacapavir) in children and teens aged 2 to 17 who already have their HIV under control with other complex daily medications. The goal is to see if this simpler, two-drug pill is safe and works well in…

This study tests a new experimental drug called CL-197 in 24 adults with HIV-1 who have never taken any HIV medication. The goal is to see how well the drug lowers the amount of virus in the blood and to check for side effects over about two weeks. Participants will receive a sin…

This study looks at whether semaglutide, a drug already used for weight loss, can help people with HIV who are obese lose more weight than just diet and exercise. About 80 adults with well-controlled HIV will take semaglutide or follow standard lifestyle advice for 28 weeks. Rese…

This study tests a long-acting HIV medicine called lenacapavir in teens and children (weighing at least 35 kg) who have tried other HIV drugs before. The goal is to see if the drug is safe, tolerable, and works well when combined with other HIV medications. Participants will rece…

This study looks at whether a medication called SGLT2 inhibitor, already used for diabetes and kidney disease, can improve blood flow to the heart in women with HIV who also have diabetes or kidney problems. About 80 women will be randomly assigned to health education alone or he…

This study tests a phone-based therapy called Acceptance and Commitment Therapy (ACT) to help people with HIV who drink too much. Researchers will compare ACT to a standard brief intervention in 300 adults. The goal is to see if ACT reduces alcohol use and improves symptoms of de…

This study is checking how well a new rapid test called TruPlex works for detecting HIV, Hepatitis B, and Syphilis. About 1,000 adults who are at risk or have symptoms will take part. Trained staff will use the test and answer questions about how easy it is to use and read the re…

This study follows 5,000 HIV-negative adults in Italy who are taking pre-exposure prophylaxis (PrEP) to prevent HIV. Researchers will track how well PrEP works in everyday life, monitor side effects, and understand why some people stop taking it. The goal is to improve HIV preven…

This early-stage study tests a vaginal gel called MucoCept-CVN, made from a modified version of a natural vaginal bacterium that releases an anti-HIV drug. The goal is to see if it is safe for healthy women and whether it can be cleared with antibiotics. If successful, it could b…

This study tests whether adding the drug tesamorelin to a home exercise program improves physical function in adults aged 50-80 with HIV who are sedentary and show early signs of frailty. Half of the 100 participants will get tesamorelin and half a placebo, all while exercising w…

This study looks at how well people with HIV who have developed resistance to the drug dolutegravir can suppress the virus with current treatments. Researchers will track 6,600 participants across multiple countries to understand resistance patterns and improve care. The goal is …

This study looks at how a type of talk therapy for depression changes the gut microbiome, immune system, and brain activity in 150 adults living with both HIV and depression. Participants will receive either the therapy or standard care, and researchers will use brain scans and o…

This study looks at how cannabis ingredients (THC and CBD) affect decision-making, attention, and motivation in people with and without HIV. About 138 adults aged 18-65 who use cannabis infrequently will take either THC, CBD, or a placebo for 5 days. Researchers will measure chan…

This study looks at how mothers with HIV in the United States decide to feed their babies, whether by breastfeeding or formula. Researchers will interview and survey about 1,150 mothers and their families to understand the medical, social, and personal factors behind these choice…